Adalimumab denials in California external review
In the California DMHC record, independent physician reviewers decided 35 published external-review cases involving Adalimumaband overturned the plan’s denial in 68.6%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Conditions behind Adalimumab denials
| Category | Decisions | Overturned |
|---|---|---|
| Psoriasis | 8 | 100% |
| Crohn's Disease | 7 | 71.4% |
| Psoriatic Arthritis | 4 | 50% |
| Ulcerative Colitis | 3 | 33.3% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 32 | 65.6% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 3 | 100% |
What the reviewers wrote
Where the denial was overturned
The patient is a 36-year-old man with Crohn’s disease of the ileocolon for at least four years with a diagnosis established at surgery. He has been treated with Asacol, prednisolone, methonidazole, mercaptopurine, Entocort, and, most recently, infliximab. In September 2004, the patient underwent a small bowel resection and stricturoplasty and the specimen was examined by the pathologist who thought this again represented active Crohn’s disease. Although the patient had some initial response to infliximab, the response has waned with time. Citing theoretical reasons including antibody production to this agent, the enrollee and his providers have requested that the Health Plan approve adalimumab (Humira) as treatment for Crohn’s disease.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Humira. Psoriasis is a chronic, immune-mediated dermatological disorder characterized by an accelerated hyperproliferation of keratinocytes leading to the formation of erythematous plaques that can affect any part of the body. Some patients with psoriasis develop psoriatic arthritis. The treatment options for moderate-to-severe plaque psoriasis include topical therapies such as high-potency corticosteroids, vitamin D analogs, topical retinoids, and calcineurin inhibitors. Phototherapy options include narrowband ultraviolet B (UVB), psoralen ultraviolet A (PUVA), and excimer laser. Systemic treatments involve immunosuppressants and biological therapies.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: The patient’s parent has requested authorization and coverage for Humira 40 mg/0.4 mL pen, quantity of four per 28 days. There is a lack of evidence in current medical literature supporting the use of the requested medication regimen for the treatment of enthesitis-related arthritis subtype of juvenile idiopathic arthritis and juvenile ankylosing spondylitis. Mistry and colleagues note that management of enthesitis-related arthritis includes NSAIDs with physical therapy.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Humira subcutaneous injection. The records provided for review document that this patient has inflammatory bowel syndrome (IBS) substantiated by Rome IV criteria. However, there is a lack of support for a diagnosis of inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis. The patient’s provider has recommended treatment with adalimumab (Humira), which is an anti-tumor necrosis factor (TNF) medication. Anti-TNF agents such as Humira have not been demonstrated to be beneficial for the treatment of patients with IBS.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
Why plans deny Humira — and what reviewed cases show
This page covers the Humira auto-injector dosage form, which the source data counts separately. The medication, the denial patterns, and the appeal strategy are the same — see the full Humira record here.
Humira (adalimumab) is FDA-approved for: crohn's disease (adults and children 6 and older); ulcerative colitis (adults and children 5 and older); rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. An on-label indication can be important evidence when a denial frames the requested use as unproven or cosmetic.
Forced switch to a biosimilar
Adalimumab now has many FDA-approved biosimilars, and formularies increasingly cover only their preferred version. The denial isn't a judgment that adalimumab is wrong for you — it's a contracting decision about which adalimumab. If you're stable on brand Humira, the question the exception process weighs is whether switching risks your remission, and that's your prescriber's call to document.
Step therapy — “try conventional therapy first”
For Crohn's and colitis, plans commonly require documented failure of conventional agents (aminosalicylates, corticosteroids, immunomodulators) before covering a biologic. Denials usually cite missing documentation of those trials, not a clinical dispute — the trials happened, but never made it into the prior-auth request.
Continuation denied after a plan or formulary change
New plan year, new employer, or a formulary shuffle can un-approve therapy that has kept you in remission for years. Continuity-of-care arguments are strongest exactly here: the plan needs a clinical reason to interrupt working treatment, and “our contract changed” is not one.
Dose and interval limits
IBD dosing sometimes needs intensification your gastroenterologist prescribes based on response and drug levels. Quantity-limit denials treat that as excess supply. The prescriber's rationale — disease activity, drug-level monitoring, prior response — is what the exception process exists to consider.
Step-therapy and forced-switch requirements yield to a documented exception: your prescriber attests to prior failures, contraindications, or clinical reasons this specific agent is appropriate. Pharmacy exception processes run on deadlines measured in hours to days once that supporting statement is in.
Evidence cited in overturned Humira decisions
- Anchor to the diagnosis and disease severity the chart documents — Crohn's disease and ulcerative colitis are FDA-approved indications, not off-label uses.
- List every conventional agent tried, with dates, doses, and outcomes — that paragraph alone defeats most step-therapy denials.
- If you're stable on current therapy, make remission the centerpiece: describe what uncontrolled disease looked like and have your prescriber state the clinical risk of switching or interrupting.
- Demand the specific criteria document and the exact formulary language the denial relied on.
The published California record contains 35 external-review decisions involving Humira; 68.6% were overturned. This historical rate does not predict another case. For the full class-wide picture — step therapy, biosimilar switching, dose caps, and the record for every IBD biologic — see the Crohn’s & colitis biologic appeal guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Adalimumab, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY